# Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT02050009** · PHASE1 · WITHDRAWN · sponsor: **Fox Chase Cancer Center**

## Conditions studied

- Ovarian Papillary Serous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** metformin hydrochloride
- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02050009
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2014-10
- **Final completion:** 2014-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study was never opened to accrual
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050009, "Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02050009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*